PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

NEW YORK, May 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01171153/PharmaPoint-Multiple-Sclerosis---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's Avonex (IFNß-1a) and Merck's Rebif (IFNß-1a), and Teva's Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Similar to India, China has a low prevalence of MS, despite its large population. However, a large proportion of physicians surveyed in this report still use the Poser criteria, which relies almost exclusively on clinical examination. Therefore, given the lack of sensitive tools, such as MRI, to aid in diagnosis, it is highly possible that the actual size of the MS population in China is significantly underestimated. The key drivers of growth in this market include government initiatives to increase healthcare access, the increased availability of advanced diagnostic tools due to strong economic growth in the country, as well as the launch of new oral DMTs. These factors are expected to collectively enhance treatment rates during the forecast period.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

- Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Multiple Sclerosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents

1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Classification of Multiple Sclerosis 16
3.2 Symptoms 18
3.2.1 Prognosis 19
3.2.2 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis 21
4.2 Treatment Overview 24
4.2.1 Management of Acute Relapse 25
4.2.2 Treatment with Disease-Modifying Therapies 25
4.2.3 Symptomatic Therapies 28
4.3 China 29
4.3.1 Diagnosis 29
4.3.2 Clinical Practice 29
5 Competitive Assessment 31
5.1 Overview 31
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles – Major Brands 33
5.3.1 Betaseron/Betaferon (interferon beta-1b) 33
5.3.2 Avonex (interferon beta-1a) 37
5.3.3 Rebif (interferon beta-1a) 42
5.3.4 Copaxone (glatiramer acetate; copolymer-1) 46
5.3.5 Tysabri (natalizumab) 50
5.3.6 Gilenya/Imusera (fingolimod; FTY720) 54
5.3.7 Aubagio (teriflunomide) 59
5.3.8 Other Disease–Modifying Therapies 63
6 Opportunity and Unmet Need 64
6.1 Overview 64
6.2 Unmet Needs 65
6.2.1 Currently Available MS Drugs Only Provide Partial Benefits 65
6.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 66
6.2.3 Effective Treatments for Progressive MS Are Still Elusive 67
6.2.4 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 68
6.2.5 The Lack of Predictive Biomarkers Delays MS Diagnosis 69
6.3 Unmet Needs Gap Analysis 69
6.4 Opportunities 70
6.4.1 Treatments for Progressive MS 70
6.4.2 Targeting Patients with Clinically Isolated Syndrome 71
7 Pipeline Assessment 72
7.1 Overview 72
7.2 Promising Drugs in Clinical Development 73
7.2.1 BG-12 (dimethyl fumarate; BG00012) 76
7.2.2 Lemtrada (alemtuzumab) 80
7.2.3 Laquinimod (ABR-215062) 85
7.2.4 Daclizumab High-Yield Process (HYP) 90
7.2.5 Ocrelizumab (RG1594) 94
7.2.6 Siponimod (BAF-312) 98
7.2.7 NU-100 (interferon beta-1b) 101
7.2.8 Masitinib (AB-1010) 104
7.2.9 Tcelna (imilecleucel-T) 107
8 Market Outlook 112
8.1 China 112
8.1.1 Forecast 112
8.1.2 Key Events 115
8.1.3 Drivers and Barriers 115
9 Appendix 117
9.1 Bibliography 117
9.2 Abbreviations 128
9.3 Methodology 132
9.4 Forecasting Methodology 132
9.4.1 Diagnosed MS patients 132
9.4.2 Percent Drug-Treated Patients 132
9.4.3 Drugs Included in Each Therapeutic Class 133
9.4.4 General Pricing Assumptions 133
9.4.5 Individual Drug Assumptions 134
9.4.6 Generic Erosion 138
9.4.7 Pricing of Pipeline agents 138
9.5 Physicians and Specialists Included in This Report 139
9.6 Primary Research – Prescriber Survey 140
9.7 About the Authors 141
9.7.1 Analysts 141
9.7.2 Global Head of Healthcare 142
9.8 About GlobalData 143
9.9 Contact Us 143
9.10 Disclaimer 143

List of Tables

Table 1: Common Presenting Symptoms of Multiple Sclerosis 18
Table 2: Factors That Can Affect Prognosis in Multiple Sclerosis 19
Table 3: Revised 2010 McDonald Criteria for the Diagnosis of Multiple Sclerosis 22
Table 4: Treatment Guidelines for Multiple Sclerosis 24
Table 5: Top Three Disease-Modifying Therapies Prescribed for Multiple Sclerosis by Market 26
Table 6: Pharmacotherapy for Common Multiple Sclerosis Symptoms 28
Table 7: Disease-Modifying Drugs for the Treatment of Multiple Sclerosis, 2012 33
Table 8: Product Profile – Betaseron 34
Table 9: Betaseron/Betaferon SWOT Analysis, 2012 37
Table 10: Product Profile – Avonex 39
Table 11: Avonex SWOT Analysis, 2012 42
Table 12: Product Profile – Rebif 43
Table 13: Rebif SWOT Analysis, 2012 45
Table 14: Product Profile – Copaxone 47
Table 15: Copaxone SWOT Analysis, 2012 49
Table 16: Product Profile – Tysabri 51
Table 17: Tysabri SWOT Analysis, 2012 54
Table 18: Product Profile – Gilenya 55
Table 19: Gilenya SWOT Analysis, 2012 58
Table 20: Product Profile – Aubagio 60
Table 21: Aubagio SWOT Analysis, 2012 62
Table 22: Summary of Alternative MS DMTs, 2012 63
Table 23: Overall Unmet Needs – Current Level of Attainment 64
Table 24: Clinical Unmet Needs – Gap Analysis, 2012 70
Table 25: Multiple Sclerosis – Phase Pipeline, 2012 73
Table 26: Comparison of Therapeutic Classes in Development for Multiple Sclerosis, 2012 75
Table 27: Product Profile – BG-12 77
Table 28: BG-12 SWOT Analysis, 2012 80
Table 29: Product Profile – Lemtrada 82
Table 30: Lemtrada SWOT Analysis, 2012 85
Table 31: Product Profile – Laquinimod 87
Table 32: Laquinimod SWOT Analysis, 2012 90
Table 33: Product Profile – Daclizumab High-Yield Process 91
Table 34: Daclizumab SWOT Analysis, 2012 94
Table 35: Product Profile – Ocrelizumab 95
Table 36: Ocrelizumab SWOT Analysis, 2012 98
Table 37: Product Profile – Siponimod 99
Table 38: Siponimod SWOT Analysis, 2012 101
Table 39: Product Profile – NU-100 102
Table 40: NU-100 SWOT Analysis, 2012 104
Table 41: Product Profile – Masitinib 105
Table 42: Masitinib SWOT Analysis, 2012 107
Table 43: Product Profile – Tcelna 108
Table 44: Tcelna SWOT Analysis, 2012 111
Table 45: Sales Forecasts ($m) for Multiple Sclerosis in China, 2012–2022 113
Table 46: Key Events Impacting Sales for Multiple Sclerosis in China, 2012 115
Table 47: Multiple Sclerosis Market in China – Drivers and Barriers, 2012 115
Table 48: Physicians Surveyed, By Country 140

List of Figures

Figure 1: Accrual of Disability in the Four Subtypes of Multiple Sclerosis 17
Figure 2: Expanded Disability Status Scale (EDSS) 23
Figure 3: Current Algorithm for the Treatment of MS with Disease-Modifying Therapies 27
Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Multiple Sclerosis, 2012–2022 74
Figure 5: Sales for Multiple Sclerosis in China by Drug Class, 2012-2022 114

To order this report:
Pathology Industry: PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022

__________________________

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker